dc.contributor.author
Lachmann, Nils
dc.contributor.author
Duerr, Michael
dc.contributor.author
Schoenemann, Constanze
dc.contributor.author
Pruss, Axel
dc.contributor.author
Budde, Klemens
dc.contributor.author
Waiser, Johannes
dc.date.accessioned
2018-06-08T10:33:42Z
dc.date.available
2017-04-21T11:50:52.719Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/20660
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-23960
dc.description.abstract
Throughout the past years we stepwise modified our immunosuppressive treatment
regimen for patients with antibody-mediated rejection (ABMR). Here, we
describe three consecutive groups treated with different regimens. From 2005
until 2008, we treated all patients with biopsy-proven ABMR with rituximab
(500 mg), low-dose (30 g) intravenous immunoglobulins (IVIG), and
plasmapheresis (PPH, 6x) (group RLP, ). Between 2009 and June 2010, patients
received bortezomib (1.3 mg/m2, 4x) together with low-dose IVIG and PPH (group
BLP, ). In July 2010, we increased the IVIG dose and treated all subsequent
patients with bortezomib, high-dose IVIG (1.5 g/kg), and PPH (group BHP, ).
Graft survival at three years after treatment was 73% in group BHP as compared
to 45% in group BLP and 25% in group RLP. At six months after treatment median
serum creatinine was 2.1 mg/dL, 2.9 mg/dL, and 4.2 mg/dL in groups BHP, BLP,
and RLP, respectively (). Following treatment, a significant decrease of
donor-specific HLA antibody (DSA) mean fluorescence intensity from to () was
observed in group BHP, but not in the other groups. Our results indicate that
graft survival, graft function, and DSA levels could be improved along with
stepwise modifications to our treatment regimen, that is, the introduction of
bortezomib and high-dose IVIG treatment.
en
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Treatment of Antibody-Mediated Renal Allograft Rejection
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Journal of Immunology Research. - 2017 (2017), Artikel Nr. 6872046
dc.title.subtitle
Improving Step by Step
dcterms.bibliographicCitation.doi
10.1155/2017/6872046
dcterms.bibliographicCitation.url
http://doi.org/10.1155/2017/6872046
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000026851
refubium.note.author
Der Artikel wurde in einer reinen Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000008073
dcterms.accessRights.openaire
open access